U.S. News: City of Hope Is Best Cancer Hospital in the West

July 29, 2019 | Letisia Marquez

City of Hope has been named the best cancer hospital in the West by U.S. News & World Report’s 2019-20 Best Hospitals: Specialty Ranking. This marks the 13th consecutive year it has been distinguished as one of the nation’s elite cancer hospitals.

Continue Reading

Innovative approach using KITE-439 in targeting HPV-related malignancies

August 20, 2019 | City of Hope

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.

PSCA as a novel CAR T target for resistant prostate cancer

August 20, 2019 | City of Hope

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.

City of Hope enrolling patients in clinical trial for HPV-linked cancers

August 20, 2019 | Letisia Marquez

A first-in-human, phase 1 T cell trial for patients who have human papillomavirus (HPV)-associated cancers that have relapsed, or are resistant to treatment, is now open at City of Hope. The institution is the first to open such a trial on the West Coast.

City of Hope scientist receives $9.28M for CAR T trial for metastatic breast cancer

August 15, 2019 | Letisia Marquez

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

First in the nation: City of Hope to offer experimental T cell drug for liver cancer patients

August 5, 2019 | Zen Vuong

An ongoing clinical study in China on the drug showed liver tumor shrinkage, regression of metastatic tumors and fewer side effects than in other T cell clinical trials.

Caitlin's journey: Lymphoma patient gets fresh start with CAR T

July 31, 2019 | Abe Rosenberg

Diagnosed with a rare, fast-growing blood cancer and ineligible for a lifesaving stem cell transplant after failing chemotherapy, treatment with a breakthrough CAR T drug called Yescarta was Caitlin Buchanan's best hope for survival.

ASCO research highlights: First KRAS inhibitor and CAR T cell therapy for CLL

June 28, 2019 | City of Hope

At ASCO, City of Hope presented on a number of topics, but some of the most noteworthy involved the first KRAS inhibitor to show anti-tumor activity and the use of CAR T cell therapy in chronic lymphocytic leukemia.